H. Lundbeck A/S (HLUBF)
| Market Cap | 6.28B +45.1% |
| Revenue (ttm) | 3.94B +11.2% |
| Net Income | 575.42M +14.5% |
| EPS | 0.58 +14.4% |
| Shares Out | n/a |
| PE Ratio | 10.92 |
| Forward PE | 6.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 1,211 |
| Open | 5.37 |
| Previous Close | 5.50 |
| Day's Range | 5.37 - 5.50 |
| 52-Week Range | 4.59 - 6.41 |
| Beta | 0.26 |
| RSI | 52.36 |
| Earnings Date | May 13, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
Lundbeck price target lowered to DKK 40 from DKK 44 at Deutsche Bank
Deutsche Bank analyst Niall Alexander lowered the firm’s price target on Lundbeck (HLBBF) to DKK 40 from DKK 44 and keeps a Hold rating on the shares. Published first on…
Lundbeck price target lowered to DKK 50 from DKK 53 at Barclays
Barclays lowered the firm’s price target on Lundbeck (HLBBF) to DKK 50 from DKK 53 and keeps an Equal Weight rating on the shares.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...